[go: up one dir, main page]

WO2009062104A3 - Expression aberrante du transporteur de zinc zip4 (slc39a4) contribuant de manière significative à la pathogenèse et à la progression du cancer du pancréas humain - Google Patents

Expression aberrante du transporteur de zinc zip4 (slc39a4) contribuant de manière significative à la pathogenèse et à la progression du cancer du pancréas humain Download PDF

Info

Publication number
WO2009062104A3
WO2009062104A3 PCT/US2008/082892 US2008082892W WO2009062104A3 WO 2009062104 A3 WO2009062104 A3 WO 2009062104A3 US 2008082892 W US2008082892 W US 2008082892W WO 2009062104 A3 WO2009062104 A3 WO 2009062104A3
Authority
WO
WIPO (PCT)
Prior art keywords
slc39a4
progression
pancreatic cancer
human pancreatic
aberrant expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/082892
Other languages
English (en)
Other versions
WO2009062104A2 (fr
Inventor
Qizhi Yao
Min Li
Changyi Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of WO2009062104A2 publication Critical patent/WO2009062104A2/fr
Publication of WO2009062104A3 publication Critical patent/WO2009062104A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un facteur préalablement non caractérisé dans une tumeur maligne du pancréas, ZIP4, et concerne ainsi une cible pour une thérapie du cancer. Les agents qui inhibent ZIP4 fournissent des procédés et des compositions pour traiter un cancer, en particulier, le cancer du pancréas.
PCT/US2008/082892 2007-11-09 2008-11-07 Expression aberrante du transporteur de zinc zip4 (slc39a4) contribuant de manière significative à la pathogenèse et à la progression du cancer du pancréas humain Ceased WO2009062104A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98671607P 2007-11-09 2007-11-09
US60/986,716 2007-11-09

Publications (2)

Publication Number Publication Date
WO2009062104A2 WO2009062104A2 (fr) 2009-05-14
WO2009062104A3 true WO2009062104A3 (fr) 2009-12-30

Family

ID=40626458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/082892 Ceased WO2009062104A2 (fr) 2007-11-09 2008-11-07 Expression aberrante du transporteur de zinc zip4 (slc39a4) contribuant de manière significative à la pathogenèse et à la progression du cancer du pancréas humain

Country Status (1)

Country Link
WO (1) WO2009062104A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3878473A1 (fr) * 2020-03-10 2021-09-15 Universitat Pompeu Fabra Traitement et/ou diagnostic d'un type de cancer caractérisé par l'expression du transporteur de zinc zip4

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005559A2 (fr) * 2005-06-30 2007-01-11 Caprion Pharmaceuticals, Inc. Tat-005 et procedes d'evaluation et de traitement du cancer
US20070105133A1 (en) * 2005-06-13 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070105133A1 (en) * 2005-06-13 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007005559A2 (fr) * 2005-06-30 2007-01-11 Caprion Pharmaceuticals, Inc. Tat-005 et procedes d'evaluation et de traitement du cancer

Also Published As

Publication number Publication date
WO2009062104A2 (fr) 2009-05-14

Similar Documents

Publication Publication Date Title
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
IL199907A0 (en) Composition for treatment of pancreatic cancer
GB2430935A (en) Tetrapeptide analogs
WO2007127010A3 (fr) Composés de diarylthiohydantoïne
NO20076401L (no) Diarylhydantoinforbindelser
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
MY183014A (en) Compounds for enzyme inhibition
EP2152722A4 (fr) Compositions comportant des agents therapeutiques mir34 pour traiter le cancer
WO2008030883A3 (fr) Traitement du cancer
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
IL201397A0 (en) Triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
MY153243A (en) Compound for inhibiting mitotic progression
PL2478907T3 (pl) Kompozycje do leczenia nowotworu
WO2008021038A3 (fr) Pyridobenzazépines et méthodes d'inhibition de la progression mitotique
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
IL243294A0 (en) Compounds and compositions for the treatment of cancer
WO2008112290A3 (fr) Utilisation du récepteur ephb4 comme marqueur diagnostique et cible thérapeutique dans le cancer de l'ovaire
IL238394B (en) Preparations containing a combination of factors for the treatment of cancer
WO2007101148A3 (fr) Composés à base d'hexose pour traiter le cancer
WO2010065563A3 (fr) Agents thérapeutiques à base d'apratoxine : mécanisme et méthodes de traitement
MX2009012233A (es) Compuestos de triazolil aminopirimidina.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08847497

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08847497

Country of ref document: EP

Kind code of ref document: A2